Epoch Investment Partners Inc. Reduces Position in Agilent Technologies, Inc. $A

Key Points

• Epoch Investment Partners Inc. has reduced its holdings in Agilent Technologies by 4.8%, now owning 266,657 shares valued at approximately $31.19 million, after selling 13,336 shares in the first quarter.
• Analysts have mixed views on Agilent Technologies, with price targets ranging from $115.00 to $159.00 and a consensus rating of "Moderate Buy" among twelve analysts.
• CEO Padraig Mcdonnell sold 1,508 shares at an average price of $117.44, resulting in a significant reduction of his ownership stake by 3.87%.

Epoch Investment Partners Inc. lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 266,657 shares of the medical research company's stock after selling 13,336 shares during the period. Epoch Investment Partners Inc. owned 0.09% of Agilent Technologies worth $31,194,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after buying an additional 270 shares during the period. Integrated Wealth Concepts LLC grew its stake in shares of Agilent Technologies by 24.5% in the 4th quarter. Integrated Wealth Concepts LLC now owns 3,413 shares of the medical research company's stock valued at $458,000 after buying an additional 671 shares during the period. Kovitz Investment Group Partners LLC purchased a new stake in shares of Agilent Technologies in the 4th quarter valued at approximately $699,000. Coldstream Capital Management Inc. grew its stake in shares of Agilent Technologies by 11.6% in the 4th quarter. Coldstream Capital Management Inc. now owns 4,999 shares of the medical research company's stock valued at $672,000 after buying an additional 520 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Agilent Technologies by 12.3% in the 4th quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock valued at $563,259,000 after buying an additional 457,713 shares during the period.

Analyst Ratings Changes

Several analysts have recently weighed in on A shares. Leerink Partners increased their price target on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Robert W. Baird dropped their price target on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating for the company in a research note on Thursday, May 22nd. Barclays increased their price target on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research note on Tuesday, June 24th. Finally, Evercore ISI increased their price target on shares of Agilent Technologies from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Agilent Technologies presently has an average rating of "Moderate Buy" and an average price target of $138.83.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Agilent Technologies Stock Performance

Shares of A stock opened at $118.44 on Wednesday. The firm's 50 day moving average price is $117.93 and its 200-day moving average price is $116.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The firm has a market cap of $33.64 billion, a P/E ratio of 29.24, a P/E/G ratio of 3.62 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. During the same period in the prior year, the business posted $1.22 EPS. The business's revenue for the quarter was up 6.0% compared to the same quarter last year. As a group, equities research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.